
    
      A randomized, double blind, controlled trial will be conducted in general intensive care unit
      (ICU) in Tehran, Iran. After a full review of the inclusion and exclusion criteria and
      explanation of the risks and benefits of the study, written consent form will be completed.
      Intervention patients will be received 20 g/day of colostrum along with enteral formula and
      control patients will be received maltodextrin along with enteral formula. Patients will be
      evaluated for plasma endotoxin and plasma zonulin.
    
  